Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TALPHERA, INC. Director's Dealing 2011

Nov 16, 2011

35181_dirs_2011-11-16_c7f064f4-d6bc-4cea-9ab2-7fe98242374d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACELRX PHARMACEUTICALS INC (ACRX)
CIK: 0001427925
Period of Report: 2011-11-14

Reporting Person: EDWARDS MARK G (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-11-14 Common Stock P 40000 $2.90 Acquired 40000 Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.85-$3.00, inclusive. The reporting person undertakes to provide to Acelrx Pharmaceuticals, Inc., any security holder of Acelrx Pharmaceuticals, Inc., or the staff of the Securities and Exchange Comission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.